



Corporate Presentation Imaging CRO Business January, 2019



- Median Technologies, its directors, officers, advisors and employees make no representation or warranty as to statistical data or predictions contained in this presentation that were taken or derived from third party sources or industry publications; such statistical data and forecasts are used in this presentation for information purposes only.
- This presentation includes only summary information and should not be considered exhaustive. Objectives, statements and forecasts of Median Technologies contained in this document are provided only for illustrative purposes and are based on current views and assumptions of the management. These objectives, statements and forecast information, including expressed or implied statements regarding future revenues and sales, involve known and unknown risks as well as uncertainties that may affect actual results, performance or achievements of the Group which are likely to make them differ materially from those anticipated in the summary information. A certain number of factors may have consequences on actual results and developments and cause them to differ materially from those stated, whether expressed or implied, based on the forward looking statements. Median Technologies disclaims any obligation or undertaking to disseminate an update or revision of the objectives, statements and information contained in this presentation in view of likely changes in the strategy or intentions of Median Technologies or in the course of events or conditions, assumptions or circumstances used in the preparation of such information, unless requested otherwise by law.
- Median Technologies Securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act").
- These documents are disclosed in a personal capacity only and for your own information on a confidential basis to you per your confidential obligation and may not be reproduced, redistributed or published (either internally or externally to your company), directly or indirectly, in whole or in part, in any capacity whatsoever, to any other person. U.S. investors must be "Accredited Investors" as defined in Regulation D of the Rules and Regulations promulgated under the Securities Act of 1933.
- This presentation is intended only for persons who (i) have professional experience in matters relating to investments within the meaning of "investment professionals" as defined in Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion), Order 2005 (as amended) (the " Order"), (ii) who fall within the scope of Article 49 (2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order, (iii) are not in the United Kingdom, or (iv) to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issuance or sale of securities may be lawfully communicated to or caused to be communicated to (all such persons together being referred to as "Qualified Persons"). This presentation is intended for Qualified Persons only and cannot be given to persons who are not Qualified Persons. Any investment or investment activity to which this presentation refers is permitted for Qualified Persons only and will be denied to any other person.



Median Technologies is listed on Euronext Growth market
ISIN: FR0011049824 - ticker: ALMDT

Median Technologies Imaging CRO Solutions

The Imaging CRO in Oncology

- A powerful blend of Technology, Science and Service
- iSee[®], a unique imaging solution for clinical trials based on proprietary technology
- A team of talented and dedicated people



- **2002 - Company created** – extracting the most meaning out of medical images
- **2006 – LMS (*iSee*®) becomes a Medical Device** – Deployment to hospitals through the world
- **2009 – first iCRO services:** First to large pharmas, Quintiles, then global
- **2016 – iBiopsy® initiated:** Artificial Intelligence Platform in Imaging Diagnostics
- **2018 - split iBiopsy® & iCRO** – Global reorganization
 - iCRO becomes a focused Business Unit, breakeven & sustainable
 - Offices in Europe (Sophia-Antipolis), USA (Woburn) and Asia (Shanghai, HK)

Oncology Imaging Solutions and Services

Bringing the power of Imaging Phenomics to the entire patient journey

- Develop cloud AI software solutions and services for the interpretation and monitoring of oncology imaging and cancer patients
- Standardize and automate the interpretation of medical images in oncology and assess patient response to therapy



CLINICAL TRIALS

*Improve and optimize
the assessment of
new cancer
drugs in clinical trials*



PATIENT CARE

*Improve screening,
diagnosis and
monitoring standards
of cancer patients*

iSee[®]

iBiopsy[®]

Imaging CRO Solutions and Services

Automated and standardized image management: iSee®




- Image analysis and data management platform
- Extracts more data from an image than any other system
- Delivers the highest quality data for better informed decisions


- Limits variability and increases reproducibility by automatically identifying, quantifying, and tracking lesions across all time points
- All readers use this advanced proprietary tool, accessed through a web-browser
- Based on a 510K FDA cleared platform

Scientific Expertise for Clinical Trials


- Immuno-oncology imaging criteria and experience
- Integrated assessment and side by side comparison of routine and advanced imaging biomarkers for more informed decisions (RECIST, iRECIST, mRECIST, irRC, RECIL, Lugano, RANO, volumetric assessment, etc.)
- Scientific expertise in imaging protocol design



Pulmonary nodule volume assessment



Lesion density assessment (Histogram)



Liver lesion RECIST measurement

What it Means for our Sponsors and Partners

Best choice for your study

For early phase studies:

Faster Go/No Go Decisions

- Access to advanced criteria and novel imaging biomarkers, seamless comparison to RECIST
- Short TAT with on-going reads
- Eligibility and Progressive Disease confirmation with provision of comprehensive report and images
- Integration of data into CRO/Sponsor database
- Engagement and flexibility of small dedicated experienced teams

What it means for you: More meaningful data in regard to disease evolution and faster Go/No Go decisions

For later phase studies:

FDA Registration

- Global reach, proven expertise
- Quality data generated by imaging system based on an FDA-cleared medical device
- January 2017 FDA audit with no findings
- Eligibility and Progressive Disease confirmation with comprehensive reports and images to support the evidence
- Approvals: 7 regulatory approvals, 4 indications and 3 drugs

What it means to you: Integrity of data, better dossiers for FDA submission and value dossiers for payers

For Partners:


The Best Imaging Partner

- True Integration at all operational and technical levels
 - Start-up activities: site initiation, feasibility, trainings with SIV, test transfer for CRA monitoring, escalation, etc.
- Consulting/ expertise to complement and enhance RFPs
- High engagement and flexibility of small dedicated teams
- Full end to end integration with AGmednet workflow tools

What it means for you: a differentiated offering for your biopharma sponsors

Experience Around the Globe

Geographic breakdown of site location by the number of unique sites



Experience by Phase

(66 Studies)


		Including Trials with Immunotherapy
16	Phase I trials	6
9	Phase I/II trials	6
27	Phase II trials	7
14	Phase III trials	9

Supported 7 Regulatory approvals!
3 Drugs for 4 Indications

Approved by some top 5
Audited by FDA & major pharmas

A Sustainable Plan for Growth

Pushed by development in China



Median Technologies Business Strategy in China

Chinese based entity delivering locally focused iCRO services to the Greater China market

2018

- Limited local presence (1 BD, 1PM)
- Gross New Business achieved well above target
- Signed most major Chinese big pharmas
- HK entity registered
- WFOE in Shanghai

2019

- Planning to register a Chinese JV that could go public in Hong Kong
- Potentially raising funds from Chinese investors
- Deploy operations in China, including local readers
- Become market leader in China

- Break-Even and Sustainable Business
- Amazing potential in China
- Looking for partners to grow further & faster





Thank you!

Our Core Values

Leading innovation with purpose

Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases.

Committing to quality in all we do

Be dedicated to quality in everything we do. Quality begins with us and we are committed to it.

Supporting our customers in achieving their goals

Listen to the needs of our customers and help make their goals our goals through our innovation, imaging expertise, superior services and quality solutions.

Putting the patient first

There is a person at the other end of the images we analyze who is counting on us to do everything we can to help make them healthier.

